Key result
Overexpression of miR-30c by rAAV system attenuated cardiomyocyte apoptosis and cardiac dysfunction in db/db mice by targeting PGC-1β and reducing PPARα transcriptional activity.
Why the study?
Metabolic abnormalities are implicated as a causal event in diabetic cardiomyopathy, but the mechanisms underlying cardiac metabolic disorder were not fully understood.
miR-30c protects against diabetic cardiomyopathy by targeting PGC-1β and reducing PPARα transcriptional activity, suggesting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Supports miR-30c targeting in diabetic cardiomyopathy models; hypothesis-generating and requires human validation before clinical consideration.
BACKGROUND: Metabolic abnormalities have been implicated as a causal event in diabetic cardiomyopathy (DCM). However, the mechanisms underlying cardiac metabolic disorder in DCM were not fully understood. RESULTS: Db/db mice, palmitate treated H9c2 cells and primary neonatal rat cardiomyocytes were employed in the current study. Microarray data analysis revealed that PGC-1β may play an important role in DCM. Downregulation of PGC-1β relieved palmitate induced cardiac metabolism shift to fatty acids use and relevant lipotoxicity in vitro. Bioinformatics coupled with biochemical validation was used to confirm that PGC-1β was one of the direct targets of miR-30c. Remarkably, overexpression of miR-30c by rAAV system improved glucose utilization, reduced excessive reactive oxygen species production and myocardial lipid accumulation, and subsequently attenuated cardiomyocyte apoptosis and cardiac dysfunction in db/db mice. Similar effects were also observed in cultured cells. More importantly, miR-30c overexpression as well as PGC-1β knockdown reduced the transcriptional activity of PPARα, and the effects of miR-30c on PPARα was almost abated by PGC-1β knockdown. CONCLUSIONS: Our data demonstrated a protective role of miR-30c in cardiac metabolism in diabetes via targeting PGC-1β, and suggested that modulation of PGC-1β by miR-30c may provide a therapeutic approach for DCM.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2019) studied Diabetic cardiomyopathy. rAAV-miR-30c vs. rAAV-miR-random was evaluated on Cardiac dysfunction and metabolic derangement (p=<0.05). Overexpression of miR-30c by rAAV system attenuated cardiomyocyte apoptosis and cardiac dysfunction in db/db mice by targeting PGC-1β and reducing PPARα transcriptional activity.
Synapse has enriched 10 related papers. Consider them for comparative context: